drugset / Trial / NCT02911480
Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin
RandomizedCrossoverOpen-labelOther
Summary
The current study is designed as a phase I multiple dose study to evaluate the pharmacokinetics and bioavailability of \[14C\]-labelled oxytocin in healthy women.
Timeline
- Start
- 2016-04
- Primary completion
- 2017-02
- Completion
- 2017-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxytocin | Peptide | 0.1 iu | Intravenous |
| Subject | Oxytocin | Peptide | 1 iu | Intravenous |
| Subject | Oxytocin | Peptide | 10 iu | Intravenous |
| Subject | Oxytocin | Peptide | 20 iu | Intravenous |
| Subject | Oxytocin | Peptide | 200 iu | Intravenous |
Indications
No indication recorded.